Myelodysplastic Syndrome (MDS) Clinical Trials

Find Myelodysplastic Syndrome (MDS) Clinical Trials Near You

Bexmarilimab Plus Azacitidine in a Randomized, Double-blind, Placebo-controlled Phase IIb Trial in Treatment-naïve Higher-risk Myelodysplastic Syndromes (HR-MDS)

Status: Recruiting
Location: See all (30) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This Phase IIb study (BEXERA) will evaluate the safety and efficacy of bexmarilimab (FP-1305), an antibody targeting Clever-1, given in combination with azacitidine compared with azacitidine plus placebo in adults with treatment-naïve higher-risk myelodysplastic syndromes (HR-MDS). Participants will be randomized to receive bexmarilimab at one of two dose levels (1 mg/kg or 3 mg/kg) plus azacitidine, or placebo plus azacitidine. The primary aim is to select the recommended dose of bexmarilimab for subsequent development based on a predefined integration of clinical response and safety/tolerability.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Participant provides written informed consent.

• Participant is ≥18 years of age.

• Participant has newly diagnosed MDS with morphologically confirmed HR-MDS as defined according to 2022 World Health Organization classification (5th Edition, Annex 7).

∙ IPSS-M classification of moderately high risk, high risk, and very high risk.

‣ \<20% bone marrow blasts per bone marrow biopsy/aspirate at screening

• Participant is eligible for azacitidine per local practice and willing to initiate trial therapy.

• Participant has ECOG performance score 0 to 2.

• Participant has life expectancy ≥3 months.

• Participant has adequate organ function: creatinine clearance ≥30 mL/min (Cockcroft-Gault); indirect (unconjugated) bilirubin ≤1.5 times the upper limit of normal (ULN) (unless related to Gilbert's syndrome, in which case the indirect bilirubin levels must be \<3×ULN for inclusion); aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤3×ULN.

• Participant has baseline leukocyte count of \<20×109/L. Hydroxycarbamide use is permitted to meet this criterion.

• Women of childbearing potential have a negative pregnancy test; participants of childbearing potential (and their partners) agree to use highly effective contraception during treatment and for ≥6 months after last dose.

⁃ Participant is willing and able to comply with protocol procedures and follow up.

Locations
United States
California
City of Hope Medical Center
NOT_YET_RECRUITING
Duarte
Colorado
University of Colorado Cancer Center
NOT_YET_RECRUITING
Aurora
Connecticut
Yale Cancer Center
NOT_YET_RECRUITING
New Haven
Florida
Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System
NOT_YET_RECRUITING
Pembroke Pines
Massachusetts
Mass General Brigham Cancer Institute
NOT_YET_RECRUITING
Boston
North Carolina
University of North Carolina Lineberger Comprehensive Cancer Center
NOT_YET_RECRUITING
Chapel Hill
Tennessee
Vanderbilt University Medical Center
NOT_YET_RECRUITING
Nashville
Texas
The University of Texas MD Anderson Cancer Center
NOT_YET_RECRUITING
Houston
Wisconsin
Medical College of Wisconsin - Clinical Cancer Center - Froedtert Hospital
NOT_YET_RECRUITING
Milwaukee
Other Locations
Finland
Helsinki University Hospital Comprehensive Cancer Center
NOT_YET_RECRUITING
Helsinki
Oulu University Hospital
NOT_YET_RECRUITING
Oulu
Tampere University Hospital
NOT_YET_RECRUITING
Tampere
Turku University Hospital
NOT_YET_RECRUITING
Turku
France
CHU de Bordeaux
NOT_YET_RECRUITING
Bordeaux
Hôpital Saint-Louis
NOT_YET_RECRUITING
Paris
CHU de Poitiers
NOT_YET_RECRUITING
Poitiers
The Institut Gustave Roussy
NOT_YET_RECRUITING
Villejuif
Italy
AOU SS. Antonio e Biagio e Cesare Arrigo
NOT_YET_RECRUITING
Alessandria
IRCCS Azienda Ospedaliero-Universitaria di Bologna
NOT_YET_RECRUITING
Bologna
INOC - Istituto Nazionale Oncologico Candiolo
NOT_YET_RECRUITING
Candiolo
IRCCS Istituto Europeo di Oncologia
NOT_YET_RECRUITING
Milan
Poland
Pratia Onkologia Katowice
NOT_YET_RECRUITING
Katowice
Aidport Clinical Trials Hospital
NOT_YET_RECRUITING
Skórzewo
MTZ Clinical Research Powered by Pratia
NOT_YET_RECRUITING
Warsaw
United Kingdom
University Hospital Birmingham Nhs Trust
NOT_YET_RECRUITING
Birmingham
The Beatson West of Scotland Cancer Centre
NOT_YET_RECRUITING
Glasgow
King's College Hospital
RECRUITING
London
Maidstone and Tunbridge Wells NHS Trust
NOT_YET_RECRUITING
Maidstone
The Christie NHS Foundation Trust
NOT_YET_RECRUITING
Manchester
Royal Cornwall Hospitals NHS Trust
NOT_YET_RECRUITING
Truro
Contact Information
Primary
Joab Williamson, PhD
joab.williamson@faron.com
+358 2 469 5151
Backup
Petri Bono, MD, PhD
petri.bono@faron.com
Time Frame
Start Date: 2026-10
Estimated Completion Date: 2030-12
Participants
Target number of participants: 90
Treatments
Experimental: Bexmarilimab (1mg/kg) and azacitidine
Standard of care azacitidine as per label/institutional practice; Bexmarilimab weekly (Q1W), Intravenous.
Experimental: Bexmarilimab (3mg/kg) and azacitidine
Standard of care azacitidine as per label/institutional practice; Bexmarilimab weekly (Q1W), Intravenous.
Placebo_comparator: Placebo and azacitidine
Standard of care azacitidine as per label/institutional practice; Placebo weekly (Q1W), Intravenous.
Related Therapeutic Areas
Sponsors
Leads: Faron Pharmaceuticals Ltd

This content was sourced from clinicaltrials.gov

Similar Clinical Trials